Multiple Therapies,
One Virus.
KALIVIR is developing cutting-edge, next-generation
oncolytic viral immunotherapy programs for treatment
of cancer. We design safe and potent oncolytic
product candidates to treat patients across mulltiple
tumor types. Learn more about us
PRESENTATIONS – Novel Vaccinia Enhanced Template (VET) Oncolytic Platform
NEWS AND EVENTS READ MORE Oct 5, 2022 – KaliVir Immunotherapeutics to Present Data on its Novel Pre-Clinical Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) Annual Meeting here. READ MORE